Correspondence on Letter regarding "Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways".
作者信息
Lee Seung Min, Jun Dae Won
机构信息
Department of Translational Medicine, Graduate School of Biomedical Science & Engineering, Hanyang University, Seoul, Korea.
Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea.
出版信息
Clin Mol Hepatol. 2023 Jan;29(1):171-172. doi: 10.3350/cmh.2022.0381. Epub 2022 Nov 10.
Abstract
摘要
相似文献
1
Correspondence on Letter regarding "Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways".关于“金诺芬通过NRF2和NF-κB信号通路减轻非酒精性脂肪性肝病中的肝脂肪变性和纤维化”的信件往来
Clin Mol Hepatol. 2023 Jan;29(1):171-172. doi: 10.3350/cmh.2022.0381. Epub 2022 Nov 10.
2
Letter regarding "Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways".关于“Auranofin通过NRF2和NF-κB信号通路减轻非酒精性脂肪性肝病中的肝脂肪变性和纤维化”的信函
Clin Mol Hepatol. 2023 Jan;29(1):163-164. doi: 10.3350/cmh.2022.0326. Epub 2022 Oct 27.
3
Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways.金诺芬通过 NRF2 和 NF-κB 信号通路减轻非酒精性脂肪性肝病的肝脂肪变性和肝纤维化。
Clin Mol Hepatol. 2022 Oct;28(4):827-840. doi: 10.3350/cmh.2022.0068. Epub 2022 Jun 22.
4
Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait.药物重新利用以治疗非酒精性脂肪性肝炎：金诺芬，一种用于治疗特定复杂性状的金有机分子复合物。
Clin Mol Hepatol. 2022 Oct;28(4):806-809. doi: 10.3350/cmh.2022.0208. Epub 2022 Aug 19.
5
Reversing nonalcoholic fatty liver disease-related cirrhosis by inhibiting pyruvate kinase M2: a role for shikonin?通过抑制丙酮酸激酶M2逆转非酒精性脂肪性肝病相关肝硬化：紫草素的作用？
J Gastroenterol Hepatol. 2023 Aug;38(8):1447. doi: 10.1111/jgh.16273. Epub 2023 Jun 24.
6
Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the Nf-κB Pathway.水飞蓟宾通过抑制氧化应激和参与 NF-κB 通路缓解 NASH 小鼠的肝脂肪变性和纤维化。
Dig Dis Sci. 2018 Dec;63(12):3398-3408. doi: 10.1007/s10620-018-5268-0. Epub 2018 Sep 6.
7
Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.肝小异二聚体伴侣的破坏可诱导实验性非酒精性脂肪性肝炎中脂肪变性和炎症的分离。
J Biol Chem. 2020 Jan 24;295(4):994-1008. doi: 10.1074/jbc.RA119.010233. Epub 2019 Dec 12.
8
Letter to the editor: diagnosing fibrosis and cirrhosis in nonalcoholic fatty liver disease using machine learning models.致编辑的信：使用机器学习模型诊断非酒精性脂肪性肝病中的纤维化和肝硬化
Hepatology. 2023 May 1;77(5):E103-E104. doi: 10.1097/HEP.0000000000000209. Epub 2023 Jan 3.
9
2,3,5,4'-tetrahydroxystilbence-2-O-β-D-glucoside attenuates hepatic steatosis via IKKβ/NF-κB and Keap1-Nrf2 pathways in larval zebrafish.2,3,5,4'-四羟基二苯乙烯-2-O-β-D-葡萄糖苷通过 IKKβ/NF-κB 和 Keap1-Nrf2 通路减轻幼鱼脂肪变性。
Biomed Pharmacother. 2020 Jul;127:110138. doi: 10.1016/j.biopha.2020.110138. Epub 2020 May 5.
10
Effect of nuclear factor-κB and angiotensin II receptor type 1 on the pathogenesis of rat non-alcoholic fatty liver disease.核因子-κB及1型血管紧张素II受体在大鼠非酒精性脂肪性肝病发病机制中的作用
World J Gastroenterol. 2015 May 21;21(19):5877-83. doi: 10.3748/wjg.v21.i19.5877.
本文引用的文献
1
Letter regarding "Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways".关于“Auranofin通过NRF2和NF-κB信号通路减轻非酒精性脂肪性肝病中的肝脂肪变性和纤维化”的信函
Clin Mol Hepatol. 2023 Jan;29(1):163-164. doi: 10.3350/cmh.2022.0326. Epub 2022 Oct 27.
2
An overview of ferroptosis in non-alcoholic fatty liver disease.非酒精性脂肪性肝病中的铁死亡概述
Biomed Pharmacother. 2022 Sep;153:113374. doi: 10.1016/j.biopha.2022.113374. Epub 2022 Jul 11.
3
The multifaceted role of ferroptosis in liver disease.铁死亡在肝脏疾病中的多方面作用。
Cell Death Differ. 2022 Mar;29(3):467-480. doi: 10.1038/s41418-022-00941-0. Epub 2022 Jan 24.
4
Auranofin prevents liver fibrosis by system Xc-mediated inhibition of NLRP3 inflammasome.金诺芬通过系统 Xc 介导的 NLRP3 炎性小体抑制来预防肝纤维化。
Commun Biol. 2021 Jun 30;4(1):824. doi: 10.1038/s42003-021-02345-1.
5
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease.KASL临床实践指南：非酒精性脂肪性肝病的管理
Clin Mol Hepatol. 2021 Jul;27(3):363-401. doi: 10.3350/cmh.2021.0178. Epub 2021 Jun 22.
6
Recent advances in nonalcoholic fatty liver disease metabolomics.非酒精性脂肪性肝病代谢组学的最新进展。
Clin Mol Hepatol. 2021 Oct;27(4):553-559. doi: 10.3350/cmh.2021.0127. Epub 2021 Jun 8.
7
Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort.HSD17B13 基因失活变异、非酒精性脂肪性肝炎与不良肝脏结局：一项多民族亚洲队列研究结果。
Clin Mol Hepatol. 2021 Jul;27(3):486-498. doi: 10.3350/cmh.2020.0162. Epub 2021 Feb 23.
8
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective.非酒精性脂肪性肝病肝纤维化定量评估的研究进展：组织学视角。
Clin Mol Hepatol. 2021 Jan;27(1):44-57. doi: 10.3350/cmh.2020.0181. Epub 2020 Nov 19.
9
Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights.非酒精性脂肪性肝病和酒精性肝病：从临床方面到病理生理学见解。
Clin Mol Hepatol. 2020 Oct;26(4):728-735. doi: 10.3350/cmh.2020.0202. Epub 2020 Oct 1.
10
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease.抗糖尿病药物治疗非酒精性脂肪性肝病的获益。
Clin Mol Hepatol. 2020 Oct;26(4):430-443. doi: 10.3350/cmh.2020.0137. Epub 2020 Aug 14.
Zotero 插件